This brand name is authorized in United States.
The drug YUVIWEL contains one active pharmaceutical ingredient (API):
1
|
UNII
Y3BH8M899D - NAVEPEGRITIDE
|
|
CNP released from navepegritide has the same receptor binding affinity and activity as endogenous CNP. Like endogenous CNP, CNP released from navepegritide binds to NPR-B, stimulating an increase in cyclic guanosine monophosphate (cGMP) and signaling through protein kinase G, resulting in an inhibition of the MAPK signaling pathway and thereby antagonizing the overactive FGFR3 signaling in achondroplasia. CNP promotes chondrocyte differentiation and proliferation, thereby stimulating skeletal bone growth in patients with achondroplasia. |
|
Below package inserts are available for further reading:
| Document | Type | Information Source | |
|---|---|---|---|
| YUVIWEL Powder for solution for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| US | FDA, National Drug Code | 73362-201, 73362-202, 73362-203 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.